Regulatory Agility in a Post-Pandemic World

Marianne Yap
Head, Regulatory and Government Affairs, APAC
26 November 2021

In Partnership with the Philippines Association of Medical Device Professionals (PAMDRAP)

Alcon
SEE BRILLIANTLY

Philippine Association of Medical Device
PAMDRAP
Regulatory Affairs Professionals
"Bridging Regulatory Expertise in the Medical Device Industry"

My Affair with Regulatory Affairs – 20 Years

HSA Health Sciences Authority

Alcon SEE BRILLIANTLY

align invisalign iTero

Regulator

Industry

Sakit Ulo kasi

"It's Complicated"

Alcon SEE BRILLIANTLY

ZIMMER BIOMET Your progress. Our promise.™

BAUSCH + LOMB See better. Live better.

The Deep Blue Sea

About me...on a personal note...



Alcon

About me...on a more serious note...

- Drafted the ASEAN Medical Device Directive, ASEAN Common Submission Dossier Template (CSDT)
- Head-of-Delegation (HoD) in the Medical Device Product Working Group (MDPWG)
- Secretariat to the ASEAN Medical Device Technical Committee (MDTC)
- Ex-Chair of Asia Harmonization Working Party (AHWP) Working Groups 1 (Pre-Market Submission and CSDT) and 6 (Capacity Building and Regulatory Training)
- Liaison Member of Study Group 1, Global Harmonization Task Force (GHTF)
- Trainer to regulators/industry under capacity building programs
- Vice Chair, Capacity Building Working Group, APACMed
- Appointed lecturer for the Graduate and Advanced Certificate for Medical Devices Regulatory Affairs Programmes from the National University of Singapore.

NUS National University of Singapore

NANYANG TECHNOLOGICAL UNIVERSITY

BSC (Honours) In Pharmacology

MSC. In Biomedical Engineering

Alcon

Stage 5

New emerging SARS-CoV-2 variants and their implications

- **New SARS-CoV-2 variants:**
  - Sept. 2020, a variant emerged in Denmark related to mink farming
  - Variant detected in the United Kingdom in December 2020
  - Variant detected in South Africa in December 2020
  - 9th January 2021, variant detected in Japan among persons coming back from Brazil
- All these variants involve **genetic mutations coding for the spike protein**
- The spike protein of SARS-CoV-2 is targeted by most vaccines currently approved or in development; mutations of the spike protein are closely monitored



- **The mode of transmission of the virus variants has not changed**
- **The same preventive measures continue to be effective and should continue to be implemented**[1]

Pandemic Dashboard

Numbers at a glance

239 007 759

Confirmed cases

Last update: 14 October 2021, 11:08 pm GMT+8

4 871 841

Confirmed deaths

Last update: 14 October 2021, 11:08 pm GMT+8

6 471 051 151

Vaccine doses administered

Last update: 14 October 2021

COVID-19 and the Critical Role of Medtech

COVID-19 and the Critical Role of Medtech





COVID-19 and the Critical Role of Medtech





The Rise of Technological Advancements

Technologies That Will Shape The Post-Virus World



- Crisis can either be a catalyst or can speed up changes that are on the way.
- It almost can serve as an accelerant.
- Robot That Conducts Swab Tests For Covid-19 Is Safe, Faster And More Comfortable For Patients
- It reduces swabbers' risk of exposure to the virus and the need for training people, standardises the consistency of swabs taken, and increases the efficiency of conducting swab tests.
- This made-in-Singapore bot is the first that allows patients to fully control the swab process so they are more comfortable. Patients can activate and terminate the machine at will.

A New Era for MedTech industry

AUG 10 | MORE ON MEDICAL DEVICES

COVID-19 pandemic changing regulatory picture around medical devices, technology in healthcare

Some of these changes have presented opportunities for entrepreneurs and product developers.

Jeff Lagasse, *Associate Editor*

Alcon

COVID-19 IS ACCELERATING THE RISE OF THE DIGITAL ECONOMY

HEALTH EUROPA

Home › News › Research & Innovation News › How the COVID-19 pandemic will accelerate mobile medtech innovation

News | Research & Innovation News

How the COVID-19 pandemic will accelerate mobile medtech innovation

26th March 2021

© iStock/ipopba

A New Era for MedTech industry



“Digitally Transforming Practice"

Covid-19 pandemic: example teledentistry services satisfy the need for social distancing and minimize physical contact

Continuity of care: monitoring patients’ progress remotely to ensure their treatment is tracking to plan

Singapore authorizes four COVID-19 antigen rapid test self-use kits

Singapore authorises four COVID-19 antigen rapid test self-use kits

11 June 2021 | News

Tweet Share 1 Share

HSA is working with the Ministry of Health (MOH) to make these tests widely available through designated local retail pharmacies

- HSA is working with the Ministry of Health (MOH) to make these tests widely available through designated local retail pharmacies.

- The Health Sciences Authority (HSA) in Singapore has granted interim authorization for four antigen rapid test self-test kits.

- These are antigen rapid tests (ARTs) that can be used by consumers (untrained lay-users) for self-testing to detect active SARS-CoV-2 infection in nasal swab samples. ARTs detect the viral proteins in the nasal swab samples of infected individuals and usually work best in the early stages of infection. ARTs can achieve a sensitivity of about 80% for cases with higher viral loads and a specificity range of 97-100%.

Technological Agility: Fundamental Shifts in a Post Covid-19 World

COVID-19 has accelerated the following trends which are reshaping the future of healthcare.









Source: https://www.rsm.global/singapore/insights/our-expert-insights/beyond-covid-19-technological-advancements-healthcare

How Singapore is Embracing Innovative Technology and Robots in Healthcare

Interest in medtech set to grow as S'pore healthcare firms digitalise

More doctors and users have signed up to use telehealth platform Doctor Anywhere, which allows users to consult a doctor through video on an app. PHOTO: DOCTOR ANYWHERE

Sue-Ann Tan

UPDATED APR 19, 2021, 3:27 PM

SINGAPORE - The Covid-19 pandemic has spurred many firms and sectors to transform themselves digitally, and even the healthcare sector with its high degree of human touch is not exempt.

The interest in medical technology, or medtech, has grown markedly over the past year, industry experts said.

When COVID-19 evolved rapidly across the world, hospitals had to leverage new technologies, such as artificial intelligence (AI) and analytics, to develop tools that can be swiftly deployed, and enable teams to find new ways to combat the virus and manage the situation efficiently

Alcon

Harnessing Artificial Intelligence

- Doctors in Singapore developed an AI predictive tool to determine the likelihood of whether a patient has mild or severe pneumonia, based on chest x-ray images.

- Intended use: Community- Acquired Pneumonia and COVID-19 Artificial Intelligence Predictive Engine (CAPE), this system alerts doctors to pneumonia patients who are likely to become critically ill.

- Predictive tool used to determine the likelihood of whether a patient has mild or severe pneumonia.

- The risk of patients requiring critical care can be calculated almost instantaneously.

- Doctors at the emergency department and wards can receive an early warning for possible clinical deterioration, and prescribe the appropriate measures to improve patient outcomes.

Source: https://www.singhealth.com.sg/news/singapore-health/embracing-innovative-tech-and-robots-in-healthcare

Robots on the Frontline

Meet the robots that have been on the frontlines of the COVID-19 battle, “SwabBot” and “temi”.

Source: https://www.singhealth.com.sg/news/singapore-health/embracing-innovative-tech-and-robots-in-healthcare

Availability of Antigen Rapid Test (ART) Self Test Kits Over The Counter



Every S'pore household to receive 10 ART Covid-19 self-test kits: MOH

The distribution will be done via SingPost and each household will receive a package containing 10 ART self-test kits. PHOTO: ST FILE

Clara Chong

PUBLISHED OCT 9, 2021, 3:47 PM SGT

SINGAPORE - The Health Ministry will be conducting another round of distribution of antigen rapid test (ART) kits, as Singapore heads towards a new normal where frequent testing for Covid-19 becomes common.

Source: TodayOnline, Yahoo News

Catalyst for Regulatory Agility

1 Varying Requirements

2 Basic Tenets of Regulatory Controls

3 Navigating Emergency Regulatory Mechanisms

- Formulate **emergency exemption/approval pathways** (sometimes called provisional/conditional approval) to allow **fast access** with limited preliminary clinical evidence and conditions attached to request for post-authorization submission of ongoing or additional safety and performance evidence.

- Leveraging **regulatory reliance models** and/or authorizations from overseas reference authorities (such as those in IMDRF member countries or the WHO Emergency Use Listing procedure), to minimise duplication of efforts.

Enablers of Regulatory Agility in Philippines

On the other hand the COB has issued Customs Administrative Order No. 7-2020 ("CAO 7-2020"), which provides that:

- The importation of health equipment and supplies to carry out the objective of Republic Act No. 11469 shall be exempt from duties, taxes and fees, including:
  - PPE, such as gloves, gowns, masks, goggles, face shields, surgical equipment and supplies;
  - Laboratory equipment and its re-agents;
  - Medical equipment and devices;
  - Support and maintenance for laboratory and medical equipment;
  - Surgical equipment and supplies;
  - Medical supplies, tools and consumables (i.e., alcohol, sanitizers, tissue, thermometers, hand soap, detergent, sodium hydrochloride, cleaning materials, povidine iodine, common medicines (e.g., paracetamol tablet and suspension, mefenamic acid, vitamin tabler and suspension, hyoscine tablet and suspension, oral rehydration solution, and cetirizine tablet and suspension);
  - COVID-19 testing kits; and
  - Others as may be determined by the DOH.
- Manufacturers included in the Master List of the Department of Trade and Industry and other incentive granting bodies of the National Government may avail of the tax and duty free importation under Section 4(o) of Republic Act No. 11469 for their importation of materials necessary for the production of health equipment and supplies deemed as critical or needed to carry out the objectives of Republic Act No. 11469.
- Importers of medical equipment and supplies for commercial purposes are exempt from the presentation of Certificate of Product Notification ("CPN") or Certificate of Product Registration ("CPR") issued by the FDA prior to release from the BOC provided, that they are able to provide a copy of their LTO and proof of application for product notification with the FDA. For ventilators, respirators and their respective accessories imported for commercial purposes, importers only need to present a copy of their LTO.
- Foreign donations of PPEs (face masks including N95 Masks, Shoe Covers, Gloves, Head Covers, and Gowns), imported not for commercial purposes, and foreign donations of ventilators, respirators and their respective accessories to be used in the treatment of COVID-19 patients, shall not be required clearance from the FDA prior to release.
  - Head Covers, and
  - Gowns

Enablers of Regulatory Agility in USA

Initiatives to speed up market access	Tenets of Regulatory Mechanisms
New Mechanism	The key mechanism that the FDA is employing to facilitate the urgent need for medical products is the Emergency Use Authorization (EUA). EUAs allow the use of unapproved drugs and other medical products, or unapproved uses of those products in an emergency.
Faster Review	FDA is reviewing and granting EUAs in as little as 24 hours of receiving applications.



Enablers of Regulatory Agility in UK

Initiatives to speed up market access	Tenets of Regulatory Mechanisms
New Mechanism	The MHRA may authorize manufacturers to supply a non-CE marked device in the interest of the protection of health (see here). This will be under regulations 12(5), 26(3) and 39(2) of the Medical Devices Regulations 2002, and is likely to be relevant for manufacturers of ventilators and PPE. The Department of Health and Social Care (DHSC) can grant its approval so that manufacturers may submit applications for exemption from the regulations to the MHRA. The DHSC may grant its approval regarding ventilators as long as they comply with the necessary minimum specifications which have been set out by the UK Government for ventilators.
Faster Review	The focus has been on a faster review for medicines and medical devices that are related to COVID-19, and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) may authorize manufacturers to supply a non-CE marked device in the interest of the protection of health.

Enablers of Regulatory Agility in Australia

Australian Government
Department of Health
Therapeutic Goods Administration

Therapeutic Goods Administration

An introduction to the work of Australia's regulator of therapeutic goods

Initiatives to speed up market access	Tenets of Regulatory Mechanisms
New Mechanism	• Relaxation from the requirement to obtain marketing approval for COVID-19 diagnostic test kits imported by, supplied to or used by accredited pathology laboratories • Relaxation in requirements to obtain marketing approval for certain other medical devices such as face masks, disposable gowns and protective eyewear that are supplied under a contract with the Australian Government for the purposes of the national stockpile; • Relaxation of requirements (relating to marketing approval and other technical requirements), for ventilators manufactured in Australia in accordance with minimum technical requirements prescribed by the TGA, provided that such ventilators are only supplied to Australian hospitals; and • Manufacture and supply of hand sanitizers.
Faster Review	Expedited approvals for all medical devices associated with the detection, prevention and treatment of COVID-19.

Enablers of Regulatory Agility in Japan

Initiatives to speed up market access	Tenets of Regulatory Mechanisms

New Mechanism	• The government has introduced a subsidy to businesses which intend to make investment in facilities to manufacture surgical masks.
	• MHLW announced measures to provide manufacturers in non-medical industries with easier access to the medical devices market to promote the manufacture of medical devices for COVID-19 (such as ventilators). The measures include the following:
	  • If a manufacturer manufactures only parts of medical devices and supply them to marketing authorization holders of such devices, regulatory procedures will not apply to such manufacturer.
	  • If a manufacturer is to be involved in assembly and other important manufacturing processes:
	  • regulatory registration as medical devices manufacturer will be handled on a priority and expedited basis; and
	  • a change to the product approval resulting from the addition of manufacturing sites will also be handled on a priority and expedited basis and physical QMS inspection of the manufacturing sites will be conducted after the approval of such change.

Faster Review	A foreign-manufactured test kit was approved as an IVD on 27 March on an expedited basis with a small amount of support data but subject to the condition that post-approval clinical assessment be conducted.

Enablers of Regulatory Agility in China

NATIONAL MEDICAL PRODUCTS ADMINISTRATION
国家药品监督管理局

Initiatives to speed up market access	Tenets of Regulatory Mechanisms
New Mechanism	• Emergency approvals have been available under existing regulations to allow expedited market access of medical devices if: (i) they are urgently needed for public health incidents; and (ii) there are no similar products marketed in China, or that any similar products marketed in China are insufficient to meet the particular urgent needs. • Under the *Opinions on the Urgent Importation of Unregistered Medical Devices* issued by the NMPA on 27 January 2020, medical devices that are in compliance with relevant standards in the US, EU, Japan, Australia, Korea and Canada can be urgently imported during the COVID-19 epidemic. Exemption of documents for import. • In line with these emergency measures, the PRC Customs also set up a "green channel" under which donated medical devices that tare not registered or recorded in China can be released based on local MPA's approvals.
Faster Review	Urgent approvals have been heavily utilized in response to the COVID-19 pandemic. Examples include the following: a)In vitro testing reagents for COVID-19 virus: A total of 19 testing reagents had received urgent approvals as of 16 March 2020. b)Hospital beds and isolating cabins: The Guangdong Medical Product Administration (MPA) granted conditional urgent approval for an isolating hospital bed and the Jiangsu MPA granted conditional urgent approval for an isolating cabin, both for use in preventing and controlling the spread of COVID-19. In the case of Guangdong, the approval was granted within three days from filing. c)Medical masks and protective clothing: As of 24 February 2020, 153 medical masks and 93 medical protective clothes had been urgently approved. It is worth noting that for personal protective equipment such as masks and protective clothing, the production has stabilized in China and some provincial-level MPAs have already stopped accepting applications for urgent approvals.

Enablers of Regulatory Agility in Singapore

Initiatives to speed up market access	Tenets of Regulatory Mechanisms
New Mechanism	From 31 January 2020, importers of the following medical devices will not require an importer's licence from HSA: • Surgical masks; • Particulate respirators (e.g. N95 masks); • Thermometers for measuring human body temperature; and • Any protective gear for medical professionals (e.g. isolation gowns and gloves). Importers of such medical devices for commercial purposes (and not personal use) will only need to notify HSA of their intentionat least 24 hours before importation, and provide information on the brand and quantity of the devices to be imported into Singapore. The HSA has also implemented greater regulatory flexibility to manage the increase in demand for respiratory devices for COVID-19 patients. The Pandemic Special Access Route (PSAR) is an interim authorization to supply an "emergency medical device" under regulation 13C of the Health Products (Medical Devices) Regulations.
Faster Review	HSA has created an alternative regulatory pathway where registrants will not need to undergo the standard change notification process for upgrades or modifications made to registered ventilators and accompanying accessories that do not create undue risk to users, or for registration of new models of accessories for use with the registered ventilators. Registrants may implement these changes without waiting for HSA's approval.

In Summary

- **MedTech continues to evolve and develop a risk-based Covid-19 Response Plan**
- **How to qualify for emergency use authorization?**
- **Enhance collaboration amongst stakeholders to enable regulatory agility**

76 www.leadership.ng Leadership Newspapers cleadership NGA LEADERSHIP Friday June 12, 2020

Fighting COVID-19 To Build A Global Community Of Health For All

A press conference on the release of a white paper on fighting COVID-19 held by China's State Council Information Office in Beijing, capital of China, June 7, 2020.

BY ZHOU FINGJIAN

The Covid-19 global pandemic is the most extensive to affect humanity in a century. A serious crisis for the entire world, and a daunting challenge, it poses a grave threat to human life and health. This is a war that humanity has to fight and win. China, through arduous efforts, has for now succeeded in cutting off channels for the transmission of the virus. Having forged the idea that the world is a global community of shared future, and believing that it must act as a responsible member, China has fought shoulder to shoulder with the rest of the world.

On June 7, 2020, the State Council Information Office of China published a white paper titled "Fighting Covid-19 China in Action". The 37,000-word document records the Chinese people's battle against the virus, share with the international community China's experience in curbing the virus and clarifies China's stance in fighting the virus.

The Covid-19 virus has spread faster and wider than any other since the founding of the People's Republic in 1949, and has proven to be the most difficult to contain. It is both a crisis and a major test for China. Under the personal command of President Xi Jinping and the leadership of the Communist Party of China (CPC), the whole nation has waged an all-out people's war on the virus. Thanks to the people-centered governance philosophy of the CPC and China's ability to mobilize resources to accomplish major initiatives, the Chinese government has acted swiftly to fight the virus and provide medical treatment for patients. It has adopted the most thorough, rigorous and comprehensive prevention and control measures, enforced quarantine and isolation on a scale never seen before, and rapidly mobilized the manpower and resources of the whole nation and done everything possible to protect the lives and health of its people.

Through painstaking efforts and tremendous sacrifice, and having paid a heavy price, China has succeeded in turning the situation around. The White Paper, which faithfully records five stages and 126 important moments in a timeline of China's fight against the epidemic, demonstrates key policies, measures and achievements of China in coping with the epidemic. In little more than a single month, the rising spread of the virus was contained; in around two months, the daily increase in domestic coronavirus cases was held below to single digits, and in approximately three months, a decisive victory was secured in the battle to defend Hubei Province and its capital city of Wuhan. As of the end of May, a cumulative total of 83,017 confirmed cases had been reported on the Chinese mainland, 78,307 infected had been cured and discharged from hospital, and 4,634 people had died. This demonstrates a cure rate of 94.3 percent and a fatality rate of 5.6 percent.

The Covid-19 is currently raging all over the world, and lives are being lost every day. The situation in Nigeria and Africa remains grave as well. In the face of the serious crisis humanity once again stands at a crossroads. Every country has a choice to make. China believes that all countries should make the choice that is right for the interests of all humanity and the wellbeing of our future generations. Upholding the vision of a global community of shared future, we should support each other and join hands to contain the spread of the virus, and protect the health and wellbeing of people across the globe.

China has been carrying out exchanges and cooperation with the international community from the outset. It has strengthened high-level communication, shared information, and cooperated in scientific research with international organizations and other countries, and done all it can to provide assistance, contributing ingenuity and strength to the global fight against the coronavirus.

President Xi has personally promoted international cooperation. On May 18, he addressed the opening of the 73rd World Health Assembly, calling for a joint effort on the part of all countries to overcome the virus and build a global community of health for all. Xi's proposals were put forward to do everything we can for Covid-19 control and treatment, to support the WHO in leading the global response, to provide greater support for Africa, to strengthen global governance in public health, to restore economic and social development, and to strengthen international cooperation. He also announced a series of major measures that China would take in supporting the global fight, including US$2 billion of assistance and over two years, the establishment of a global humanitarian response depot and hub in China to cooperation with the United Nations, the establishment of a cooperation mechanism for Chinese hospitals to pair up with 30 African hospitals, the building of the Africa Center for Disease Prevention and Control headquarters to help the continent ramp up its disease preparedness and control capacity, the Covid-19 vaccine to be used as a global public product once it is developed and deployed in China, and the implementation of the Debt Service Suspension Initiative for the poorest countries together with other G20 members.

China has shared information and experience with the international community. China wasted no time in releasing information such as the whole coronavirus genome sequence and the specific protocols and probes for detecting the coronavirus to the WHO and other relevant countries and regional organizations, and has kept them informed with regular updates. The "delay" and "cover-up" accusations fabricated by politicians from certain countries are totally groundless and scapegoating. The National Health Commission has worked out diagnosis, treatment, prevention and control solutions, had them translated into three languages, and shared them with over 180 countries including Nigeria. China has held video conferences with health experts from over 170 countries to share our proven protocols of diagnosis, treatment and control without any reservation. Among them, Chinese medical experts have held over 30 virtual exchanges with the African side. Nigerian Health Minister Dr. Osagie Ehanire has consecutively attended all 4 video conferences on technical exchange on Covid-19 between China and Africa.

China has provided humanitarian assistance to the international community. Even while under the tremendous pressure of coronavirus control, China has moved quickly to provide as much assistance to the international community as it can. It has provided two batches of cash support totaling US$30 million to the WHO. China has been active in providing medical aid to other countries. As of the end of May, China had sent 29 medical expert teams to 27 countries, and offered assistance to 150 countries and 4 international organizations. A total of 8 teams with 148 medical workers have been sent to 11 African countries and 2 batches of governmental medical supplies have been donated to the Nigerian government. The medical teams so far organized over 400 online and offline training sessions in this regard. Local governments, enterprises, non-governmental organizations and individuals in China have donated materials to more than 150 countries and regions, and international organizations through various channels.

As the White Paper said, "The pandemic will have a significant impact on the development of humanity, but the people's longing for a happy life will remain unchanged. Peace, development, and win-win cooperation will prevail." The great force running through this arduous journey has become China's firm confidence and strong will to overcome difficulties and challenges, to support the country and the world to jointly protect the lives and health of the people, to safeguard the common homeland of mankind, and to jointly build a global community of health for all.

Pinglian is ambassador of China to Nigeria

hot topics latin america

Pandemic Response | DOI:10.1145/3422826

A Technological and Innovative Approach to COVID-19 in Uruguay

BY GASTÓN MILANO, DIEGO VALLESPIR, AND ALFREDO VIOLA

THIS ARTICLE PRESENTS a technological and innovative approach developed to help the Uruguayan government in their fight against COVID-19. The first version of the system (with only the most urgent services at that time) was released only seven days after the first case of COVID-19 was reported in Uruguay! At press time, some months after its first release, the fourth version is operative. Part of the system is a cellphone app available freely to the public, and it was downloaded by half a million people in a country with a population of 3.5 millions.

The project is innovative because it is the only world-wide solution, that we are aware of, that integrates in a unified way for patients, all health services of a country, the Ministry of Health, self-monitoring, remote patient monitoring, and telemedicine. Furthermore, the system makes full tracking possible from end to end to follow citizens' and patients' situation. Because of this, Uruguay was one of the first three countries and the first in Latin America to incorporate exposure notifications for COVID-19.

As we write this article (July 2020), the world is immersed in a contest of total uncertainty regarding health issues caused by the coronavirus. In Uruguay, the first case of COVID-19 was confirmed on March 13, 2020. The same day, a CoronaVirus UY Plan was launched by the Uruguayan government, where technology (as in South Korea and other countries) had to play a key and strategic role.

Some of the main objectives to be achieved were:

- avoid the collapse of the health system;
- avoid having to directly contact the possibly infected people by phone calls;
- be proactive in managing the epidemic;
- the software products had to be robust and extremely secure, due to the data they would handle; and,
- have an operative solution as soon as possible.

To achieve these objectives, a team of private and public companies collaborated as well as interested individuals, organizing themselves to carry out a software engineering project never seen before, at least in Uruguay.

The Uruguayan government (through the President's Board) asked the group to work quickly to achieve a first delivery in less than seven days. This first version had to include at least registration, classification based on epidemiology surveys that would make it possible to understand which citizens were more likely to have the virus, and it had to communicate about them to different health providers (using multiple channels) by telephone or a video call protecting in this way the health personnel.

This was, as the reader has probably already noticed, a mission-critical project to be executed in a few days.

Uruguay is one of the first countries to incorporate contact tracing for COVID-19.

FEATURE FEATURE 33

Covid-19 crisis: Through solidarity, we will prevail

'Now as the US is facing a severe situation domestically, many Chinese companies and localities have been offering assistance to the American people. The two peoples have shown mutual understanding and support in this joint fight against the pandemic.'

Source: https://www.greenlight.guru/blog/author/jon-speer

Embracing the Future: Role of RA Professionals like ikaw at ako

Source: https://www.greenlight.guru/blog/author/jon-speer

Anticipate

Agility

Resilience

Empathy

Collaboration

Advocacy

Game Changer

Disclaimer

The information provided in this presentation represents the personal opinions of the Speaker and does not necessarily represent the opinions of his employer. The information is not intended as legal or regulatory advice, as specific advice often turns on specific facts. Companies relying on the information do so at their own risk and assume the risk of any subsequent liability that results from relying on the information.


Alcon
SEE BRILLIANTLY